{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:40:36Z","timestamp":1785454836793,"version":"3.56.0"},"reference-count":30,"publisher":"European Respiratory Society (ERS)","issue":"3","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.ersjournals.com\/user-licence"}],"funder":[{"DOI":"10.13039\/501100005627","name":"Universit\u00e9 de Li\u00e8ge","doi-asserted-by":"publisher","award":["Fonds special a la recherche grant to Christophe J"],"award-info":[{"award-number":["Fonds special a la recherche grant to Christophe J"]}],"id":[{"id":"10.13039\/501100005627","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["Doctoral fellowship to Joseph Jorssen"],"award-info":[{"award-number":["Doctoral fellowship to Joseph Jorssen"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["EOS 30565447"],"award-info":[{"award-number":["EOS 30565447"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["T.0052.18 REGEOS"],"award-info":[{"award-number":["T.0052.18 REGEOS"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006673","name":"Fonds L\u00e9on Fredericq","doi-asserted-by":"publisher","award":["Credit de fonctionnement to Joseph Jorssen"],"award-info":[{"award-number":["Credit de fonctionnement to Joseph Jorssen"]}],"id":[{"id":"10.13039\/501100006673","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2021,7,30]]},"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:p>Neutralising antibodies against the cytokine interleukin (IL)5 have become widely used for the control of severe eosinophilic asthma. Remarkably, patients receiving neutralising anti-IL5 biological therapies retain a very stable population of residual blood eosinophils. Whether these residual eosinophils are endowed with particular biological activity has not yet been studied, but is of importance in predicting potential long-term effects of IL5 neutralisation in patients. To tackle the effect of IL5 depletion on residual eosinophils, we used a comparative RNA-sequencing approach and compared the gene expression programme of eosinophils arising in IL5-depleted or IL5-replete human or murine hosts, at steady-state<jats:italic>in vivo<\/jats:italic>and following<jats:italic>in vitro<\/jats:italic>stimulation with the eosinophil-activating alarmin IL33. We compared blood eosinophils from patients with severe allergic eosinophilic asthma treated with anti-IL5 mepolizumab therapy to those of healthy controls and matched asthma patients receiving anti-IgE omalizumab therapy. We made similar comparisons on bone marrow eosinophils from mice genetically deficient or not for IL5. We report that restriction of IL5 availability did not elicit any detectable transcriptional response in steady-state residual eosinophils in mepolizumab-treated patients or IL5-deficient mice, and influenced only a handful of genes in their response to IL33. Together, these results support the notion that treatment with IL5 neutralising antibodies spares a pool of circulating residual eosinophils largely resembling those of healthy individuals.<\/jats:p>","DOI":"10.1183\/13993003.00935-2021","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T14:31:45Z","timestamp":1630593105000},"page":"2100935","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Anti-IL5 mepolizumab minimally influences residual blood eosinophils in severe asthma"],"prefix":"10.1183","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-9127","authenticated-orcid":false,"given":"Glenn","family":"Van Hulst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Jorssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Henket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Schleich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Bureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-2449","authenticated-orcid":false,"given":"Christophe J.","family":"Desmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"2024102102363955000_59.3.2100935.1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.24.021605.090720"},{"key":"2024102102363955000_59.3.2100935.2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049"},{"key":"2024102102363955000_59.3.2100935.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0808991"},{"key":"2024102102363955000_59.3.2100935.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"2024102102363955000_59.3.2100935.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31322-8"},{"key":"2024102102363955000_59.3.2100935.6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.rmed.2019.04.020","article-title":"Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma","volume":"152","author":"Graff","year":"2019","journal-title":"Respir Med"},{"key":"2024102102363955000_59.3.2100935.7","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"2024102102363955000_59.3.2100935.8","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.immuni.2019.03.022","article-title":"GM-CSF, IL-3, and IL-5 family of cytokines: regulators of inflammation","volume":"50","author":"Dougan","year":"2019","journal-title":"Immunity"},{"key":"2024102102363955000_59.3.2100935.9","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.195"},{"key":"2024102102363955000_59.3.2100935.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80294-0"},{"key":"2024102102363955000_59.3.2100935.11","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathmechdis-012419-032756"},{"key":"2024102102363955000_59.3.2100935.12","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jaip.2020.08.039","article-title":"Clinical development of mepolizumab for the treatment of severe eosinophilic asthma: on the path to personalized medicine","volume":"9","author":"Pavord","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024102102363955000_59.3.2100935.13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"2024102102363955000_59.3.2100935.14","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/cea.13601","article-title":"Real-world experience with mepolizumab: does it deliver what it has promised?","volume":"50","author":"Schleich","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2024102102363955000_59.3.2100935.15","first-page":"27","article-title":"Transcription factor and cytokine regulation of eosinophil lineage commitment","volume":"27","author":"Mack","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"2024102102363955000_59.3.2100935.16","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1382"},{"key":"2024102102363955000_59.3.2100935.17","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.95"},{"key":"2024102102363955000_59.3.2100935.18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00101"},{"key":"2024102102363955000_59.3.2100935.19","doi-asserted-by":"crossref","first-page":"113963","DOI":"10.1016\/j.bcp.2020.113963","article-title":"Eosinophil diversity in asthma","volume":"179","author":"Van Hulst","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"2024102102363955000_59.3.2100935.20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85664"},{"key":"2024102102363955000_59.3.2100935.21","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.6.ats9-00"},{"key":"2024102102363955000_59.3.2100935.22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2024102102363955000_59.3.2100935.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2008.04.005"},{"key":"2024102102363955000_59.3.2100935.24","doi-asserted-by":"crossref","first-page":"e0217807","DOI":"10.1371\/journal.pone.0217807","article-title":"Comparison of IL-33 and IL-5 family mediated activation of human eosinophils","volume":"14","author":"Angulo","year":"2019","journal-title":"PLoS One"},{"key":"2024102102363955000_59.3.2100935.25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1301465"},{"key":"2024102102363955000_59.3.2100935.26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00058"},{"key":"2024102102363955000_59.3.2100935.27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1003029"},{"key":"2024102102363955000_59.3.2100935.28","doi-asserted-by":"publisher","DOI":"10.1038\/nm896"},{"key":"2024102102363955000_59.3.2100935.29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1400732"},{"key":"2024102102363955000_59.3.2100935.30","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201611-2234OC"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00935-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:47:11Z","timestamp":1740376031000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00935-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3,17]]},"published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1183\/13993003.00935-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00935-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}